Author: Ravi Shankar

Exploratory research results presented at Psych Congress 2026 in New Orleans

Full poster presentation can be found on “Publications” section of Company’s website

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) — Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented positive exploratory data at Psych Congress 2026 in New Orleans. The poster highlights a potential efficacy signal for fasedienol nasal spray, the Company’s rapid-onset Phase 3 product candidate, observed in a public speaking challenge study involving participants with very severe social anxiety disorder.

The research presented by Vistagen in a poster supports fasedienol’s potential for individuals with very severe social anxiety disorder, as defined by a baseline Liebowitz Social Anxiety Scale (LSAS) score of 95 or higher. In subpopulation analyses, one post-hoc and one prespecified, from two randomized, double-blind, placebo-controlled clinical trials, participants with very severe (LSAS >=95) social anxiety disorder experienced improvements in anxiety symptoms following treatment with fasedienol compared with placebo as measured by the Subjective Units of Distress Scale (SUDS).

“The positive potential efficacy signals observed in these analyses of fasedienol in very severe social anxiety disorder participants are encouraging and provide important insights into our understanding of its role in social anxiety disorder,” said Dr. Angel S. Angelov, Chief Medical Officer of Vistagen. “These findings, including the potential benefit of repeat dosing, help inform our ongoing evaluation of fasedienol.”

The post-hoc analysis of the subpopulation of very severe subjects from the randomized, double-blind, placebo-controlled portion of the PALISADE-4 Phase 3 clinical trial showed a statistically significant benefit of fasedienol on average SUDS scores during the public speaking challenge (PSC), although the study did not meet its primary endpoint in the total population. In an exploratory, randomized, double-blind, placebo-controlled Phase 2a repeat dose study (RDS), prespecified analysis of the subpopulation of participants with very severe social anxiety showed a statistically significant improvement following a single dose of fasedienol on average SUDS scores during the PSC, and an even greater numerical improvement after a second dose of intranasal fasedienol taken 10 minutes after the first. Significant improvements on pre-PSC anticipatory anxiety in both the total population and in the very severe population in the RDS also were observed, suggesting a second dose of fasedienol administered 10 minutes after the first could improve anticipatory anxiety.

Favorable safety and tolerability results in the study participants with very severe social anxiety disorder were consistent with the overall population in the two studies presented in the poster and with previous trials, and no serious drug-related safety signals were identified.

To read the full poster, please visit our “Publications” page under “Fasedienol”.

About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of rapid-onset neurocircuitry-focused intranasal product candidates called pherines. Vistagen’s pherine product candidates are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options, if successfully developed and approved. Vistagen’s most advanced intranasal pherine product candidates are fasedienol for the acute treatment of social anxiety disorder, itruvone for treatment of major depressive disorder, and refisolone for treatment of vasomotor symptoms (hot flashes) due to menopause. Connect at www.vistagen.com.

Forward-looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including, without limitation, the ability of the research presented by Vistagen to support the potential of fasedienol nasal spray as an active drug for individuals with very severe social anxiety disorder and the meaningfulness of the efficacy signals observed in the analyses, including the potential benefit of repeat dosing of fasedienol which remain subject to change upon completion of a full analysis and audit of the complete data set from the study. These forward-looking statements involve known and unknown risks that are difficult to predict and include all matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “project,” “outlook,” “strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “strive,” “goal,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Vistagen and its management, are inherently uncertain. As with all pharmaceutical products, there are substantial risks and uncertainties in the process of development and commercialization, and actual results or developments may differ materially from those projected or implied in these forward-looking statements. There can be no guarantee that any of Vistagen’s product candidates, including fasedienol, will successfully complete ongoing or future clinical trials within estimated timelines or at all, receive regulatory approval or be commercially successful. These risks and others are more fully discussed in the section entitled “Risk Factors” in Vistagen’s Annual Report on Form 10-K for the period ended March 31, 2026, and Quarterly Report on Form 10-Q for the period ended June 30, 2026, as well as discussions of potential risks, uncertainties, and other important factors in our other filings with the U.S. Securities and Exchange Commission (SEC). Vistagen’s SEC filings are available on the SEC’s website at www.sec.gov. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing Vistagen’s views as of any subsequent date. Vistagen explicitly disclaims any obligation to update any forward-looking statements other than as may be required by law. If Vistagen does update one or more forward-looking statements, no inference should be made that Vistagen will make additional updates with respect to those or other forward-looking statements.

Investor Inquiries: 
IR@vistagen.com

Media Inquiries: 
media@vistagen.com

JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) — Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company developing controllable, allogeneic CAR-T therapies for patients with cancer, for up to $47 million. The investment will help advance AvenCell’s pipeline, including AVC-201 for the treatment of relapsed/refractory acute myeloid leukemia (AML) and AVC-203 for the treatment of B-cell malignancies.

Under the terms of the agreement, Ligand has committed up to $41 million in exchange for a mid single-digit to low double-digit royalty on worldwide annual net sales of all current and future AvenCell pipeline assets, including AVC-201 and AVC-203, with the applicable rate determined based on the total amount ultimately funded. The capital will be funded in four tranches: with the first payable at closing, and the remaining three tranches payable upon achievement of certain predetermined clinical milestones and other specified financing conditions. Ligand has also committed up to $6 million in concomitant Series C financing, details of which will be announced separately.

“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to date with AVC-201, highlights the potential of AvenCell’s platform across a broad range of diseases. We look forward to working closely with the AvenCell team as it advances its pipeline of next-generation cell therapies.”

AvenCell was founded in 2021 combining switchable CAR-T technology developed by GEMoaB GmbH (now AvenCell Europe GmbH) with Intellia’s CRISPR/Cas9-based Allogeneic Engineering Technology to develop next-generation cell therapies designed to overcome key limitations of existing CAR-T treatments. AvenCell’s proprietary platform is designed to enable readily available, “off-the-shelf” cell therapies with greater control over CAR-T activity and the potential for broad application across hematologic malignancies and autoimmune diseases.

The company’s lead program, AVC-201, is an anti-CD123 CAR-T currently in a Ph1b expansion trial for the treatment of relapsed or refractory AML. AvenCell is also advancing AVC-203, a Phase 1a program for B-cell malignancies.

“We are excited to have the support and expertise of the Ligand team as we look to advance our pipeline programs through the clinic,” said Andrew Schiermeier, President & CEO of AvenCell. “This investment provides us critical resources to support the continued development of these potentially important new treatment options for patients impacted by these difficult-to-treat cancers.”

Hogan Lovells Cadwalader served as legal advisor to Ligand.

About Ligand
Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 200 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network. For more information, visit www.ligand.com or follow Ligand on X and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to the expected funding and use of proceeds under the financing arrangement; satisfaction of conditions to, and the timing and amount of, future royalty and equity investments; the development, regulatory progress, clinical performance, safety, efficacy, commercial potential and potential indications of AVC-201, AVC-203 and AvenCell’s platform and other products; the potential for AvenCell’s technologies to address limitations of existing CAR-T therapies; future sales of covered products; Ligand’s expected receipt of royalties; and Ligand’s royalty portfolio strategy and expected revenue characteristics. These statements are based on various assumptions and on the current expectations of Ligand’s management and are not predictions of actual performance. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions, many of which are beyond Ligand’s control. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the possibility that conditions to future funding are not satisfied or that optional investments are not made; AvenCell’s ability to use the financing as anticipated and to continue funding its operations and development programs; the preliminary nature of clinical data and the limited number of patients evaluated to date; the possibility that results observed in early-stage clinical trials may not be replicated in later or larger trials; adverse events, safety issues or unfavorable benefit-risk profiles; delays or failures in clinical development, patient enrollment, manufacturing, regulatory interactions or regulatory approvals; the possibility that additional or randomized clinical trials may be required; manufacturing, supply-chain, comparability and scalability challenges associated with cell therapies; competition from existing and future therapies; intellectual property risks, including the possibility that pending patent applications do not issue or provide meaningful protection; Ligand’s reliance on AvenCell, its license partners, manufacturers and other third parties to develop, manufacture and commercialize covered products and to calculate and pay royalties; the possibility that covered products are never approved or commercialized, or that sales are lower than expected; the scope and duration of Ligand’s royalty rights under the definitive agreements; and the other risk factors discussed under the heading “Item 1A. Risk Factors” in Ligand’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on February 27, 2026, and Ligand’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026, filed with the SEC on May 8, 2026 and August 7, 2026, respectively. Ligand cautions against placing undue reliance on these forward-looking statements, which speak only as of the date of this press release, and undertakes no obligation to update any forward-looking statements except as required by law.

Contacts

Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761

Media:
Kellie Walsh
media@ligand.com
(914) 315-6072

Tripled ridership, more than 50% lower cost per ride, and rapid transit infrastructure deployment

TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) — Argo Corporation (TSXV: ARGH) (OTCQX: ARGHF) (“Argo” or the “Company”) today announced that average daily transit ridership in the Town of Bradford West Gwillimbury (“BWG” or the “Town”) has grown to more than 3x the daily ridership of the Town’s previous fixed-route transit system.

Argo launched its proprietary Smart Routing™ transit infrastructure and service in BWG in April 2025. The Town subsequently replaced its previous privately operated fixed-route service with Argo’s on-demand public transit and renewed and expanded its agreement with Argo.

Argo Smart Routing™ Transit in Bradford West Gwillimbury, Canada

• Tripled Ridership: Average daily ridership has grown to more than 3x pre-Argo levels.
• Increased Transit Connections: As previously reported, Argo drove a more than 5x increase in transit connections to Bradford GO.
• Point-to-Point Access: Residents are now picked up where they are and dropped off where they are going, with over 90% of Argo trips including a pickup or drop-off more than 100 metres from the previous fixed-route bus stops.
• Lower Cost per Ride: As previously reported, the Town’s cost per ride declined by more than 50% compared with its previous fixed-route service.
• Rapid Deployment: Argo launched the infrastructure, technology and operations required for Smart Routing™ approximately three months from contract signing.
• Provincial Funding: Ontario has awarded BWG $4,093,337 through the Ontario Transit Investment Fund to support further expansion of on-demand transit.

“Bradford shows how modern transit technology can expand access to opportunity and independence, and give people the freedom to participate fully in their communities,” said Praveen Arichandran, Co-founder and CEO of Argo. “We’re bringing integrated transit infrastructure and operations online in weeks, not years, so more people can realize those benefits sooner.”

Since the BWG launch, Argo has continued the expansion of its Smart Routing™ network in Brampton and Caledon. The Company’s focus remains on expanding the network across Canada, the United States, and internationally.

About Argo

Argo delivers the first-ever vertically and publicly integrated city transit system, designed to augment public transportation and create a network of intelligently routed vehicles that work together to serve and scale to the needs of entire cities, putting people in control of their mobility. Learn more at www.rideargo.com.

Investor Contact Praveen Arichandran Co-founder & CEO Argo Corporation (800) 575-7051	Media Contact Christina Ra Argo Corporation christina@rideargo.com (800) 575-7051

Forward-Looking Information

This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward-looking statements are frequently identified by such words as “may”, “will”, “plan”, “expect”, “anticipate”, “estimate”, “intend” and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. The forward-looking information set out in this news release relates to future events or future performance and includes, without limitation, statements concerning the continued operation and expansion of Smart Routing™ in Bradford West Gwillimbury, the use of provincial funding to support further expansion of on-demand transit, the anticipated benefits of Argo’s Smart Routing™ transit system, potential future expansion to other municipalities, and the Company’s plans to expand its network in Canada, the United States and internationally, the Company’s deployment timelines.

Such forward-looking statements are based on a number of assumptions, including: the continued successful operation of the Bradford West Gwillimbury service; maintaining municipal agreements in good standing; receiving required third-party approvals, consents and integrations; operational readiness; ridership adoption levels; technology performance and reliability; the availability and use of government funding; the availability of municipal procurement opportunities and execution of definitive agreements with new municipalities; and general economic conditions. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including but not limited to: operational challenges; failure to meet contractual requirements; loss of required operating authority, insurance or approvals; third-party integration delays or failures; technology failures or cybersecurity incidents; termination or non-renewal of municipal agreements; failure to secure new municipal contracts; regulatory changes; availability of financing; and general economic conditions. Additional risks and uncertainties are described in more detail in the Company’s securities filings available at www.sedarplus.ca. Actual events or results may differ materially from those projected in the forward-looking statements and readers are cautioned against placing undue reliance thereon. The Company assumes no obligation to revise or update these forward-looking statements except as required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6a8d2001-14f6-42a3-b0f6-87401547a9eb

Integrated exploration model identifies multiple priority epithermal and porphyry targets across Fishpot; ~2,000-metre maiden drill program prepares for launch; Company commences trading on OTCQB under INXGF

VANCOUVER, British Columbia, Sept. 24, 2026 (GLOBE NEWSWIRE) — GoldInxs Mining Corp. (“GoldInxs,” or the “Company”) (TSXV: INXS, OTCQB: INXGF) is pleased to announce it has received results from a 53.4-line-kilometre 3D Induced Polarization (“IP”) survey, reprocessed Airborne Magnetic Survey data and a Virtual DRILL™ Elemental Harmonic Resonance (“EHR”) survey on its flagship Fishpot property in Central British Columbia. The combined results have refined multiple priority exploration targets where geophysical responses coincide with surface geology, alteration and geochemical anomalies ahead of the Company’s planned ~2,000-metre maiden drill program.

The Company is also pleased to report that its common shares have commenced trading on the OTCQB Venture Market under the symbol “INXGF“, an important step in broadening GoldInxs’ shareholder base, enhancing accessibility for U.S. investors and providing an additional platform for market visibility as the Company advances its exploration programs in British Columbia.

The integrated geophysical results identified and refined multiple chargeability, resistivity and magnetic features that correlate with existing geological, alteration and surface geochemical information, providing the Company with a more robust framework for prioritizing drill targets ahead of its planned ~2,000-metre maiden drill program. The Virtual DRILL™ Elemental Harmonic Resonance (“EHR”) survey also correlates with the updated geophysical results, resulting in robust multi-discipline exploration targets (refer to the Company’s press release dated August 17, 2026). The Company continues to plan and prepare for its inaugural drill program at Fishpot, located in the broader regional setting of Artemis Gold’s Blackwater Mine and Evolution Mining’s optioned Clisbako property, providing exposure to an active and increasingly established gold exploration region.

Key Highlights

• 53.4 line-kilometer 3D IP survey identified multiple chargeability and resistivity anomalies across the Fishpot property, including responses that correlate with existing surface geology, alteration and geochemical anomalies;
• Airborne magnetic data successfully reprocessed using Magnetization Vector Intensity (“MVI”), improving interpretation of magnetic responses in areas affected by magnetic remanence;
• Virtual DRILL™ Elemental Harmonic Resonance results correlate strongly with the existing and new data, showing its potential for use on other parts of the property;
• New geophysical information evaluated as part of an integrated exploration model combining 3D IP chargeability and resistivity responses with magnetic data, Virtual DRILL™ data, geological mapping, alteration and surface geochemistry, refining priority target zones based on areas where multiple exploration datasets converge;
• Planning and targeting continues for a ~2,000-metre maiden drill program, with drill pad locations and hole orientations being finalized based on the integrated geological and geophysical model.

3D Induced Polarization Results

In late July 2026, the Company engaged SJ Geophysics to complete a 3D IP survey on the Fishpot property. Data was acquired from July 28^th to August 19^th over 53.4 line kilometers in 8 lines overlapping with the main mineralized zones on the property. Results show large zones of subsurface resistivity and chargeability anomalies, many of which correlate with the surface geochemical anomalies and geology. Of particular note is the overlapping resistivity and chargeability anomalies that underlie the Lightening Zone, as well as the chargeability high, magnetic low zone that surrounds the previously identified magnetic high “lobe”, now known as the BullsEye target. The circular magnetic and chargeability response at BullsEye is considered a priority feature for follow-up exploration and may be consistent with geological characteristics observed in copper porphyry systems; drilling will be required to test this interpretation.

The 3D IP survey provides an important additional layer of subsurface information to complement the Company’s existing surface exploration dataset. Of particular interest are areas where IP responses coincide spatially with mapped geological contacts, alteration zones and anomalous surface geochemistry. The Company believes these areas warrant additional investigation and have contributed significantly to the prioritization of drill targets for the upcoming maiden drill program.

Magnetic Survey Reprocessing Results

The previously collected airborne magnetic, radiometric, and VLF-EM survey data obtained in 2025 was provided to in3D Geoscience Inc. who reprocessed the data using Magnetization Vector Intensity (“MVI”). MVI re-models the data to reduce the impacts of magnetic remanence, which can cause certain anomalies to be offset from their true locations. Several zones of magnetic remanence were identified in the original data and the resultant MVI model improved accuracy of the data in those areas.

Virtual DRILL™

The Company has received the results from the Virtual DRILL™ EHR survey. Several target areas have been identified which correlate to the existing and newly acquired exploration data. The Virtual DRILL™ EHR survey was completed independently of the newly acquired 3D IP and reprocessed magnetic data. Several EHR target areas subsequently demonstrated spatial correlation with the updated geophysical and existing geological datasets, providing an additional layer of target validation. The maiden drill program will provide an opportunity to test selected EHR targets against conventional geological and geophysical interpretations.

The Company has now integrated six exploration datasets at Fishpot; IP chargeability, IP resistivity, magnetic data, Virtual DRILL™ EHR results, geological mapping, alteration and surface geochemistry, to prioritize areas where multiple indicators overlap.

Figure 1: Induced Polarization Survey results showing Resistivity and Chargeability.

Figure 2: Magnetics MVI reprocessing results and Virtual Drill EHR results

Drill Planning Update

Integrating the new and reprocessed geophysical data with the existing property data has allowed the Company to refine their drill targets ahead of the maiden drill program planned for the Fishpot property. Overlapping geological surface information, including geochemistry, alteration, and geological mapping data with new and updated geophysical data has highlighted several promising surface and subsurface anomalies on the property. In light of the new anomalies, the Company has created several identified priority gold-silver epithermal target zones including the ‘Lightening’ zone, the ‘Luftballon’ zone’, the ‘Thriller’ zone, the ‘Believin’ zone, the “Southside’ zone, and a copper porphyry target called the ‘BullsEye’. Further refinement will be ongoing as it relates to specific drill pad locations until drilling commences, and modifications may be made as the drill program progresses.

• Lightening Zone: Resistivity and chargeability IP anomaly overlain by intense silica alteration and overlapping geochemical anomalies.
• Luftballon Zone: Magnetic low with a moderate chargeability anomaly located north of the magnetic high lobe. Intense silica alteration with overlapping geochemical anomalies.
• Thriller Zone: Magnetic low zone with resistivity anomaly, silica “ribs” present on surface.
• Believin’ Zone: Resistivity high zone with moderate chargeability anomaly and overlapping magnetic low.
• Southside Zone: Moderate chargeability high with resistivity high contact, south side of the circular magnetic lobe.
• BullsEye: Magnetic high zone surrounded by magnetic low with moderate chargeability anomaly.

Figure 3: Fishpot exploration target areas

The maiden drill program is being designed to test multiple geological and geophysical targets across the property and provide the Company with its first systematic subsurface drilling dataset at Fishpot. Results from the drill program are expected to provide important information regarding geometry, continuity, geological controls and potential scale of mineralized systems identified through surface exploration and geophysical interpretation.

Millar Property

GoldInxs has decided to drop its interests in the Millar Property in order to focus resources on its core, road accessible and drill ready Fishpot Project given the near-term catalysts and discovery potential. The Company is actively pursuing other acquisitions of properties in North America.

Nick Michael, President and CEO of GoldInxs, commented:

“The Induced Polarization results represent one of the final pieces of information needed to further refine our drill targeting. The data has identified several compelling targets and strengthened our confidence in the areas we have prioritized for drilling. Most importantly, we are seeing strong convergence across multiple exploration datasets, allowing us to move from broad target generation to a focused maiden drill program designed to test some of the most compelling targets identified at Fishpot.The commencement of trading on the OTCQB is also an important corporate milestone for GoldInxs, supporting and improving the Company’s visibility and liquidity. It expands the Company’s accessibility to U.S. investors at an exciting stage in our exploration program, as we transition from systematic target generation toward the first drill testing at Fishpot.”

Qualified Person

The technical information contained in this news release has been reviewed and approved by Darcy Vis, P.Geo., the Qualified Person for GoldInxs Mining Corp., who is responsible for the technical information contained herein. The Company’s corporate presentation identifies Mr. Vis as the Qualified Person responsible for the technical information presented by GoldInxs.

Authorised for release by the Board of GoldInxs Mining Corp.

About GoldInxs

GoldInxs Mining Corp. (TSXV:INXS, OTCQB: INXGF) is a Canadian mineral exploration company focused on discovering and advancing a high-quality gold and copper project in Central British Columbia. The Company’s flagship asset is the Fishpot Property, a large epithermal gold system in central British Columbia with Blackwater-style exploration potential, and in the same region as Artemis Gold’s Blackwater Mine and Evolution Mining’s optioned Clisbako property. The Company is listed on the TSX Venture Exchange under the symbol INXS and on the OTCQB Venture Market under the symbol INXGF, and is led by an experienced management and technical team committed to disciplined exploration and value creation for shareholders.

Website: www.goldinxs.com      |     LinkedIn: LINK      |     Twitter/X: LINK

Further Information:

Barry Miller                        
Executive Chairman and Director
GoldInxs Mining Corp.
T: 778.232.1878
E: barry@goldinxs.com

Forward-Looking Statements

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively referred to herein as “forward-looking statements”) within the meaning of applicable securities legislation. Such forward-looking statements are based on a number of assumptions, which may prove to be incorrect. Assumptions have been made regarding, among other things: conditions in general economic and financial markets; accuracy of assay results; geological interpretations from exploration, survey, historic work, drilling results, timing and amount of capital expenditures; performance of available laboratory and other related services; future operating costs; and the historical basis for current estimates of potential quantities and grades of target zones. The actual results could differ materially from those anticipated in these forward-looking statements as a result of risk factors, including the timing and content of work programs; results of exploration activities and development of mineral properties; the interpretation and uncertainties of drilling results and other geological data; receipt, maintenance and security of permits and mineral property titles; environmental and other regulatory risks; project costs overruns or unanticipated costs and expenses; availability of funds; failure to delineate potential quantities and grades of the target zones based on historical data; and general market and industry conditions.

Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. Forward-looking statements in this news release include, but are not limited to, statements regarding the Company’s planned exploration activities at the Fishpot Property or any other Company properties, the timing, scope and objectives of the planned maiden drill program, the anticipated usefulness of geological, geochemical and geophysical data in refining exploration targets, potential exploration results, other prospective exploration projects, regional considerations, potential future financings of the Company and the potential benefits of the Company’s listing on the OTCQB Venture Market.

The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made. The Company undertakes no obligation to update or revise any forward-looking statements included in this news release if these beliefs, estimates and opinions or other circumstances should change, except as otherwise required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/bfe5c0b8-9313-45b3-b711-262ed618d0b8

https://www.globenewswire.com/NewsRoom/AttachmentNg/2ed00ce5-97be-4d3b-9605-544a5458b544

https://www.globenewswire.com/NewsRoom/AttachmentNg/be70e054-86fd-4d61-991f-119a8edb9357 

NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received approval from the United States Food and Drug Administration (FDA) to implement a new potency assay, T-cell Proliferation Inhibition BioAssay (TIBA), for release and stability monitoring of all new commercial product lots of its FDA-approved mesenchymal stromal cell (MSC) product Ryoncil^® (remestemcel-L-rknd).

The TIBA assay will ensure sufficient sensitivity to detect any shifts in potency of the commercial product that could arise during changes in manufacturing processes or production in new facilities. This assay will be used as part of a matrix to release each commercial batch of RYONCIL in conjunction with the existing potency assays which determine IL-2Rα inhibition and CAP (Cell Adhesion and Proliferation), as per the product’s Biologics License. Together these assays ensure that the RYONCIL product is consistent, potent, and clinically effective.

RYONCIL is the first industrially-manufactured allogeneic MSC product approved by FDA for any indication, and the only MSC product to be approved for patients with steroid-refractory acute graft versus host disease (SR-aGvHD) aged 2 months or older.¹ Mesoblast and FDA have been working closely together since RYONCIL was approved for commercial use to ensure alignment on continued advancements to the product’s manufacturing processes and implementation of assays measuring the product’s ongoing quality control.

About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast’s Ryoncil^® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.

Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil^® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.

About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.

About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and X: @Mesoblast

Footnotes / References

1. Please see the full Prescribing Information at www.ryoncil.com

Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For more information, please contact:

Corporate Communications / Investors
Paul Hughes
T: +61 3 9639 6036
Media – Global	Media – Australia
Rubenstein	BlueDot Media
Caroline Nelson	Steve Dabkowski
T: +1 703 489 3037	T: +61 419 880 486
E: cnelson@rubenstein.com	E: steve@bluedot.net.au

To Nasdaq Copenhagen

FIXING OF COUPON RATES        24 September 2026

Fixing of coupon rates effective from 1 October 2026

Effective from 1 October 2026, the coupon rates of floating-rate bonds issued by Nykredit Realkredit A/S and Totalkredit A/S will be adjusted.

Bonds with quarterly interest rate fixing
The new coupon rates will apply from 1 October 2026 to 31 December 2026:

Uncapped bonds
DK0009518896, (32H), maturity in 2027, new rate as at 1 October 2026: 2.8422% pa
DK0009546087, (32H), maturity in 2027, new rate as at 1 October 2026: 2.7408% pa
DK0009546160, (32H), maturity in 2027, new rate as at 1 October 2026: 2.7307% pa
DK0009546244, (32H), maturity in 2027, new rate as at 1 October 2026: 2.7104% pa
DK0009546327, (32G), maturity in 2027, new rate as at 1 October 2026: 2.7713% pa
DK0009547721, (32H), maturity in 2027, new rate as at 1 October 2026: 2.8422% pa
DK0009548026, (32G), maturity in 2027, new rate as at 1 October 2026: 2.8524% pa
DK0009548109, (32H), maturity in 2028, new rate as at 1 October 2026: 2.8220% pa
DK0009548299, (32H), maturity in 2028, new rate as at 1 October 2026: 2.8118% pa
DK0009549859, (32H), maturity in 2029, new rate as at 1 October 2026: 2.8017% pa
DK0009549933, (32H), maturity in 2029, new rate as at 1 October 2026: 2.8118% pa
DK0009550006, (32G), maturity in 2028, new rate as at 1 October 2026: 2.8220% pa
DK0009551244, (32H), maturity in 2027, new rate as at 1 October 2026: 2.7915% pa
DK0009551400, (32H), maturity in 2028, new rate as at 1 October 2026: 2.6800% pa
DK0009551590, (32H), maturity in 2029, new rate as at 1 October 2026: 2.7408% pa
DK0009551673, (32H), maturity in 2029, new rate as at 1 October 2026: 2.6800% pa
DK0009551756, (32H), maturity in 2028, new rate as at 1 October 2026: 2.7104% pa
DK0009551913, (32H), maturity in 2030, new rate as at 1 October 2026: 3.1370% pa
DK0009552135, (32H), maturity in 2028, new rate as at 1 October 2026: 2.8017% pa
DK0009553885, (32H), maturity in 2029, new rate as at 1 October 2026: 2.6293% pa
DK0009553968, (32H), maturity in 2029, new rate as at 1 October 2026: 2.6293% pa
DK0009554180, (32H), maturity in 2029, new rate as at 1 October 2026: 2.6395% pa
DK0009554263, (32H), maturity in 2029, new rate as at 1 October 2026: 2.6395% pa
DK0009554503, (32H), maturity in 2030, new rate as at 1 October 2026: 3.0660% pa
DK0009554776, (32H), maturity in 2030, new rate as at 1 October 2026: 2.7408% pa
DK0009555740, (32H), maturity in 2028, new rate as at 1 October 2026: 2.6293% pa
DK0009766446, (49D), maturity in 2038, new rate as at 1 October 2026: 2.6395% pa
DK0009769622, (21E), maturity in 2041, new rate as at 1 October 2026: 2.6395% pa

Questions may be directed to Investor Relations at investor_relations@nykredit.dk or Press Officer Peter Klaaborg, tel +45 44 55 14 94.

Attachment

• Fixing of coupon rates – Nykredit Realkredit – 20260924

Descartes Datamyne™ AI Agent draws on data spanning 230 markets with more than 500 million shipment records annually to deliver traceable insights in seconds 

LONDON and ATLANTA, Sept. 24, 2026 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced the Descartes Datamyne™ AI Agent, a new conversational AI capability that helps sourcing, sales, supply chain and market intelligence teams reduce global trade data research and analysis time by up to 90%, depending on the user’s experience and query complexity. Embedded in the Descartes Datamyne global trade intelligence solution, the AI Agent allows users to ask questions in natural language and returns contextual answers in seconds, supported by dynamic visualizations and the underlying shipment records.

“Geopolitical disruption, tariff volatility and shifting sourcing patterns are making trade decisions more complex and time-sensitive,” said Brian Hodgson, General Manager, Trade Intelligence at Descartes. “By making trusted trade intelligence more accessible, the Descartes Datamyne AI Agent helps organizations understand where suppliers are gaining or losing activity, how product flows are changing, where market demand is emerging and how competitors are adapting. Users move quickly from a business question to validated insights on trends, risks and opportunities while retaining visibility into the records behind the analysis.”

Descartes Datamyne covers 230 markets with more than 500 million shipment records added annually. The AI Agent makes this extensive import and export data foundation easier to access, helping users identify suppliers, monitor competitors, evaluate trade risks, develop sales opportunities, and understand changing markets. In seconds, it responds to natural-language questions with relevant data, visualizations and contextual insights.

The Descartes Datamyne AI Agent helps users:

• Ask complex trade questions in natural language without building filters, using Boolean logic or mastering database query structures;
• Validate AI-generated findings through dynamically updated data views, visualizations and drill-down access to supporting shipment records;
• Explore insights within the same environment by refining questions and investigating related companies, commodities, shipments and trade relationships;
• Analyze actual trade behavior using observed shipment activity to understand changes in suppliers, buyers, product flows and market demand, rather than company descriptions, self-reported supplier profiles or general web content; and
• Improve supply chain planning with decision-ready summaries that highlight notable trends, anomalies, sourcing opportunities and other patterns across large volumes of trade records.

“AI is most useful when it combines trusted, domain-specific data with a clear connection to the decisions customers need to make,” said Ken Wood, EVP Product Management at Descartes. “The Agent analyzes shipment-level data and presents findings alongside the records and visual evidence supporting them, allowing users to verify conclusions, refine their questions and continue exploring without leaving the platform. Embedding the Agent directly into Descartes Datamyne gives customers a more transparent and intuitive way to accelerate decision-making and respond more effectively to changing global trade conditions.”

Learn more about the Descartes Datamyne AI Agent and Descartes’ Global Trade Intelligence solutions.

About Descartes

Descartes powers more responsive, efficient, secure and sustainable international and domestic supply chains by uniting logistics-intensive businesses on its Global Logistics Network (GLN). Shippers, carriers, and logistics service providers connect and collaborate on the GLN leveraging technology, data and AI to manage last mile deliveries, domestic and international shipments, transportation rating and payment, global trade research, customs compliance and a variety of regulatory processes. Learn more about Descartes at www.descartes.com and connect with us on LinkedIn and X.

Global Media Contact
Cara Strohack                                                                     
Tel: 226-750-8050                                 
cstrohack@descartes.com  

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”) that relate to Descartes’ global trade intelligence solution offerings and potential benefits derived therefrom, and other matters. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the factors and assumptions discussed in the section entitled, “Certain Factors That May Affect Future Results” in documents filed with the Securities and Exchange Commission, the Ontario Securities Commission and other securities regulatory authorities across Canada including Descartes’ most recently filed annual and interim management’s discussion and analysis which are available under Descartes’ profile through the EDGAR website at http://www.sec.gov or through the SEDAR+ website at http://www.sedarplus.com/. If any such risks actually occur, they could, among other consequences, materially adversely affect our business, financial condition or results of operations. In that case, the trading price of our common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purpose of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. Except as required by applicable law, we do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:	Investec Bank plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Pollen Street Group Limited
(c)        Name of the party to the offer with which exempt principal trader is connected:	Investec is Joint Broker to Pollen Street Group Limited
(d)        Date dealing undertaken:	23rd September 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state “N/A”	N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Purchases	7,139	957.05	863
Ordinary shares	Sales	11,818	954.5	835

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3.        OTHER INFORMATION
        
(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)        the voting rights of any relevant securities under any option; or (ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	24th September 2026
Contact name:	Priyali Bhattacharjee
Telephone number:	+91-9768034903

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:	Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	SThree Plc
(c)        Name of the party to the offer with which exempt principal trader is connected:	Investec is Joint Broker to SThree Plc
(d)        Date dealing undertaken:	23rd September 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state “N/A”	N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Purchases	165,725	313.5	306
Ordinary shares	Sales	181,587	313.5	306

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)        the voting rights of any relevant securities under any option; or (ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	24th September 2026
Contact name:	Priyali Bhattacharjee
Telephone number:	+91-9768034903

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

Transaction is structured around a negotiated $0.0004 per-share BFCH reference value and is intended to establish a controlled public health, wellness, longevity and human-optimization platform

GREEN VALLEY, Ariz., Sept. 24, 2026 (GLOBE NEWSWIRE) — NEXT10, Inc. (OTC: NXTN) (“NEXT10” or the “Company”), through Torreon Group, Inc., today announced today announced that it has entered into a binding Letter of Intent with BitFrontier Capital Holdings, Inc. (OTCID: BFCH), a public company doing business as UNLOCKD, Inc., for a strategic transaction intended to expand NEXT10’s operating platform.

Under the LOI, the parties agreed to use $0.0004 per issued and outstanding BFCH common share as the negotiated reference value for structuring the transaction.

Subject to completion of the required closing conditions, NEXT10 is expected to contribute agreed operating businesses and assets to BFCH and ultimately acquire approximately 75% ownership of BFCH.

The $0.0004 figure is a negotiated transaction value only. It is not an independent appraisal or fairness opinion and should not be interpreted as a prediction of BFCH’s current or future trading price.

Expanding NEXT10’s Operating Platform

NEXT10 is pursuing a strategy centered on acquiring, developing and operating businesses and strategic assets across multiple sectors.

The contemplated transaction is designed to give NEXT10 a controlled public subsidiary focused on health, wellness, longevity and human optimization, while providing BFCH access to additional operating assets, management resources and acquisition capabilities.

“I have had a personal interest in regenerative medicine and the broader wellness industry for some time, and I have been evaluating wellness centers in Florida as potential acquisition opportunities,” said Garrett Reincke, President of NEXT10, Inc. “I believe regenerative medicine and advanced wellness services fit naturally within the broader health, longevity and human-optimization strategy BFCH is building. This transaction gives us a platform to evaluate those opportunities more seriously and, where the economics and operations make sense, potentially expand into that market.” 

Reincke continues, “NEXT10 is entering the sector amid continued growth in global consumer spending on wellness. According to the Global Wellness Institute, the global wellness economy reached approximately $6.8 trillion in 2024 and is projected to approach $9.8 trillion by 2029. The United States represents the world’s largest wellness market, estimated at approximately $2.1 trillion in 2024.” 

Transaction Structure

The transaction is expected to occur in stages.

At the Initial Closing, NEXT10 is expected to contribute agreed operating businesses and assets to BFCH, acquire a noncontrolling equity interest and receive representation on the BFCH Board of Directors.

The specific businesses and assets to be contributed remain subject to final designation, due diligence and definitive transaction documentation.

BFCH will also continue working toward completion of its planned independent audit.

Following completion of the audit, due diligence, definitive documentation and other closing conditions, NEXT10 is contemplated to increase its ownership position to approximately 75% of BFCH.

The parties currently intend for BFCH to remain a separately traded public company following completion of the transaction.

Strategic Alignment

BFCH, doing business as UNLOCKD, has been developing a health and wellness portfolio that currently includes Ancient Extracts, EVERMIND and 1ENERGY.

Its broader strategy is focused on health, wellness, longevity and human optimization.

The proposed transaction is intended to combine that focused platform with NEXT10’s broader operating, acquisition and asset-development capabilities.

“This is an important next step in the strategy we have been building at BFCH,” said Dr. Jordan P. Balencic, Chairman and Chief Science Officer of BFCH. “Our goal is to build a larger operating company around health, wellness, longevity and human optimization. I expect the NEXT10 relationship to rapidly expand our core mission and is intended to give us additional assets, resources and capabilities to pursue that strategy at greater scale.”

Building a Broader Health and Wellness Business

BFCH’s strategy is focused on identifying businesses and assets that management believes may benefit from additional capital, stronger operations, product development, brand optimization and expanded distribution.

NEXT10 believes the relationship could broaden the range of opportunities available to BFCH across consumer products, wellness services, technology, testing, distribution and related businesses.

The transaction also aligns with NEXT10’s broader acquisition strategy of identifying operating businesses and assets where additional capitalization, operational discipline and active management may create opportunities for growth and increased enterprise value.

About NEXT10, Inc.

NEXT10, Inc. (OTC: NXTN) is a diversified public company pursuing growth through operating businesses, strategic investments, asset development and acquisitions across multiple sectors.

The Company’s strategy is to identify businesses and assets where additional capitalization, operating discipline and active management may improve operations, generate cash flow and create long-term enterprise value.

About BitFrontier Capital Holdings, Inc. / UNLOCKD

BitFrontier Capital Holdings, Inc. (OTCID: BFCH), doing business as UNLOCKD, Inc., is building a diversified health, wellness and consumer platform focused on acquiring, developing and commercializing brands and businesses across consumer health, wellness, longevity and human optimization. You can learn more about or strategy at www.unlockdinc.com

The Company’s current portfolio includes Ancient Extracts, EVERMIND and 1ENERGY.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the contemplated transaction between NEXT10 and BFCH, the contribution of businesses and assets, the Initial Closing, the contemplated change of control, future ownership percentages, BFCH’s planned audit, potential OTCQB qualification and future business opportunities.

Forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially.

Although NEXT10 and BFCH have entered into a binding Letter of Intent, completion of the transaction remains subject to due diligence, definitive documentation, corporate approvals, accounting and financial-statement requirements, regulatory considerations and other closing conditions. There can be no assurance that the Initial Closing or contemplated change of control will occur on the proposed terms or at all.

The $0.0004 per-share amount is a negotiated transaction reference value used by the parties to structure the transaction. It is not an independent appraisal or fairness opinion and does not represent a guarantee or prediction of BFCH’s current or future market price.

There can be no assurance that BFCH will complete its audit, qualify for OTCQB or successfully complete any future acquisition, financing or strategic initiative.

Readers should not place undue reliance on forward-looking statements. NEXT10 undertakes no obligation to update or revise them except as required by applicable law.

Contact

John B. Hayden
CEO/CHAIRMAN
TORREON GROUP INC./NEXT10
ir@torreongroupinc.com